Beta Carotene
| Double-Blind, Crossover Design * | ||
| Volunteer #’s | Phase I | Phase II |
| # 1 thru # 6 | β-Carotene+ placebo |
β-Carotene+ Bioperine® |
| # 7 thru # 12 | β-Carotene+ Bioperine® |
β-Carotene+ placebo |
| * Phase I & Phase II supplementation periods occurred 12 weeks apart. | ||
| Serum Vitamin A Levels (mg/dl) | |||
| Treatment | Baseline | Day 14 | Change |
| bβ-Carotene+ placebo |
66.0 + 11.5 | 65.1 + 10.2 | -0.9 + 2.4 |
| β-Carotene+ Bioperine® |
65.2 + 11.9 | 65.0 + 10.6 | -0.2 + 2.1 |
| Comparisons (baseline vs. Day 14, placebo vs. Bioperine® at Day 14, placebo vs. Bioperine® change at Day 14) indicated no statistically significant differences. | |||
| Serum β-Carotene levels (μg/dl) | |||
| Treatment | Baseline | Day 14 | Change |
| bβ-Carotene+ placebo |
16.3 + 2.6 | 47.2 + 6.4 | 30.9 + 5.4 |
| β-Carotene+ Bioperine® |
16.0 + 3.1 | 65.8 + 9.7 | 49.8 + 9.6 |
| Comparisons (baseline vs. day 14, placebo vs. Bioperine®at Day 14, placebo vs. Bioperine® change at Day 14) indicated statistically significant differences (all p<0.0001) | |||
| Serum β-Carotene AUC Levels at Day 14 | ||
| Treatment | AUC ug/dl/day |
% Difference |
| β-Carotene+ placebo |
272.0 + 47.6 | - |
| β-Carotene+ Bioperine® |
435.2 + 74.2 | 160 |
| Comparison of AUC indicated a statistically significant difference (p<0.0001). | ||
Figure 1. Effect of Bioperine® on the mean serum β-Carotene levels during a 14 day supplementation trial.
Summary
The relative bioavailability of β-Carotene is improved during a 14 day supplementation trail when it is ingested with Bioperine®
